Lexeo Therapeutics, Inc.
LXEOCIK 0001907108 · last filing Jul 1, 2026
Insider signal
trades dated in the last 90 days · non-derivative only
146,060 bought / 57,560 sold
net +88,500 sh · −$256.6K
- buys
- 4
- sells
- 4
- insiders active
- 4
Filing tape
Filed Wed, Jul 1, 2026
- +32,694 sh · $98.6K
Bhalla Narinder Pal — Chief Medical Officer
- Granted55,000Common Stock→ 104,500 held
- Sold22,306Common Stock@ $4.42→ 82,194 held
- +7,359 sh · $20.8K
Tamayo Louis Edward — Chief Financial Officer
- Granted12,000Common Stock→ 101,665 held
- Sold4,641Common Stock@ $4.49→ 97,024 held
- +7,394 sh · $20.9K
Otero Jose Manuel — Chief Operating Officer
- Granted12,060Common Stock→ 142,148 held
- Sold4,666Common Stock@ $4.48→ 137,482 held
- +41,053 sh · $116.2K
Townsend Richard Nolan — Chief Executive Officer · Director
- Granted67,000Common Stock→ 403,764 held
- Sold25,947Common Stock@ $4.48→ 377,817 held
Insiders on this tape
- Bhalla Narinder PalChief Medical Officer
- Tamayo Louis EdwardChief Financial Officer
- Otero Jose ManuelChief Operating Officer
- Townsend Richard NolanChief Executive Officer · Director
Informational data only — not investment advice.
The institutional holdings shown here are aggregated from third-party public regulatory filings (such as SEC Form 13F). These filings are reported with a delay (generally up to 45 days after each quarter-end), are backward-looking, and may exclude short positions, non-U.S. holdings, cash, and other assets. The data may contain errors, omissions, misclassifications, or gaps, and may not reflect a manager's current positions.
All figures are provided on an "as is" basis for general information only. Nothing on this page is financial, investment, or trading advice, a recommendation, or an endorsement of any security, manager, or strategy. Do not rely on it. Independently verify any figure against the original filings and consult a qualified professional before making any financial decision. Your use is subject to our Terms of Service.